 Trxade Group, Inc. NASDAQ: MEDS an integrated drug procurement, delivery and healthcare platform, announces its wholly-owned subsidiary, Integra Pharma Solutions, has filed for an Emergency Use Authorization EUA with the U.S. Food and Drug Administration FDA in collaboration with its partnered manufacturer of the SARS-CoV-2 IgMIgG Antibody Rapid Test Kit. Under section 564 of the Federal Food, Drug, and Cosmetic Act FDC; Act, the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or when there are no adequate, approved, and available alternatives. Filing the EUA has dual purposes; first it serves as notification to FDA that Trxade Group will be distributing the test and secondly, if the EUA is approved, it enables Trxade Group to market the product for diagnostic use. 